文献速递中药与中成药合理使用中医内科

八种中药注射剂联合化疗治疗乳腺癌:比较安全性与有效性的系统评价与网状Meta分析

8 specific Chinese herbal injections combined with chemotherapy for breast cancer: a systematic review and network meta-analysis of comparative safety and efficacy.
PubMed 文献 · Front Pharmacol · 2025-10-03

该网状Meta分析纳入44项RCT、3982例患者和8种中药注射剂,比较其联合化疗治疗乳腺癌的有效性与安全性。参芪扶正注射液在提高化疗疗效、改善生活质量和CD4+/CD8+比值及抑制白细胞下降方面最优;复方苦参注射液在提升CD4+、CD8+、降低CA125及减少血小板和血红蛋白下降方面表现最佳。

要点

  • 参芪扶正注射液联合化疗在提高疗效、生活质量和免疫比值及抑制白细胞下降方面最优。
  • 复方苦参注射液联合化疗在提升CD4+、CD8+、降低CA125及减少血小板和血红蛋白下降方面最佳。
  • 康艾注射液对CD3+改善最有效,康莱特注射液对降低CEA和CA153效果最好。

核心结论

  • 参芪扶正注射液联合化疗在提高化疗疗效、改善生活质量、改善CD4+/CD8+ T细胞比值及抑制化疗后白细胞计数下降方面最有效。
  • 复方苦参注射液联合化疗在提高化疗后CD4+和CD8+、降低肿瘤标志物CA125及减少化疗后血小板和血红蛋白下降方面表现最佳。
  • 康艾注射液联合化疗对CD3+改善最有效,康莱特注射液联合化疗对降低肿瘤标志物CEA和CA153效果最好。

研究设计与样本

  • 共纳入44项符合条件的RCT,涉及3982例患者和8种中药注射剂(CHIs)。
  • 使用Stata 17.0和R 4.2.1软件分析,效应量为比值比(OR)和标准化均数差(SMD),采用累积排名曲线下面积(SUCRA)排序。

主要发现

  • 参芪扶正注射液联合化疗在提高化疗疗效、改善生活质量、改善CD4+/CD8+ T细胞比值及抑制白细胞计数下降方面排名第一。
  • 复方苦参注射液联合化疗在提高化疗后CD4+和CD8+、降低CA125及减少血小板和血红蛋白下降方面排名第一。
  • 康艾注射液联合化疗对CD3+改善排名第一,康莱特注射液联合化疗对降低CEA和CA153排名第一。

临床怎么用

  • 临床可参考本网状Meta分析结果,根据乳腺癌患者化疗期间的具体治疗目标(如提高疗效、改善免疫或减轻血液学毒性)选择相应的中药注射剂联合方案。

局限性

  • 原文未报告具体局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer (BC) poses a major threat to human health. Since the beginning of the 21st century, numerous clinical studies conducted in China have reported the therapeutic advantages of combining Chinese herbal injections (CHIs) with chemotherapy; however, comparative evaluations of different CHIs remain scarce. This multidimensional network meta-analysis was designed to compare the efficacy of various CHIs and to identify the optimal combination regimen of CHI plus chemotherapy for breast cancer treatment. METHODS: By searching multiple databases, we screened randomized controlled trials (RCTs) on Chinese herbal injections (CHIs) combined with chemotherapy interventions for breast cancer (BC) from database inception to 25 October 2024. Studies meeting inclusion criteria with methodologically sound quality were included. Data analysis was performed using Stata 17.0 and R 4.2.1 software, with odds ratio (OR) and standardized mean difference (SMD) as effect size measures. The surface under the cumulative ranking curve (SUCRA) method was applied to rank the evaluated treatment regimens. RESULTS: This network meta-analysis included 44 eligible RCTs, involving 3,982 patients and 8 CHIs. Shenqifuzheng Injection (SQFZ) combined with chemotherapy was most effective in enhancing the efficacy of chemotherapy, improving the quality of life of breast cancer patients, ameliorating the CD4+/CD8+ T-cell ratio, and inhibiting the decrease in white blood cell (WBC) count after chemotherapy. Compound Sophora Injection (FFKS) combined with chemotherapy performed best in increasing post - chemotherapy CD4+ and CD8+, lowering tumor marker CA125, and reducing post-chemotherapy platelet (PLT) and hemoglobin (HGB) declines. Kangai Injection (KA) combined with chemotherapy was most effective for CD3+ improvement. Kanglaite Injection (KLT) combined with chemotherapy had the best effect on reducing tumor markers CEA and CA153. Although a 2021 network meta-analysis (Comparative Efficacy and Safety of Chinese Herbal Injections Combined With Cyclophosphamide and 5-Fluorouracil Chemotherapies in Treatment of Breast Cancer: A Bayesian Network Meta-Analysis) examined chemotherapy combined with Chinese medicine injections for breast cancer, it was limited to the CF regimen and assessed few outcomes, with some lower-quality studies included (excluded herein). Our study improves methodology by incorporating high-quality RCTs across all chemotherapy regimens and evaluating multiple outcomes. This provides more comprehensive results, identifying SQFZ as most effective for improving response rate and Karnofsky Performance Status (KPS), thereby enhancing clinical utility. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/myprospero, identifier [CRD42024589306].

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Shi Y, Cheng J, Zhao Y, et al. 8 specific Chinese herbal injections combined with chemotherapy for breast cancer: a systematic review and network meta-analysis of comparative safety and efficacy. Front Pharmacol. 2025. PMID: 41111516. doi:10.3389/fphar.2025.1661803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。